Merck & Co., US58933Y1055

Merck stock gains 1.97 percent at the close

Published on 09/22/2026 at 23:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 22, 2026, Merck stock finished higher after a Japan approval for KEYTRUDA QLEX. The S&P 500 ended 1.49 percent higher, while Merck traded near its 52-week high.

Photorealistic wide-angle view of a modern oncology research laboratory. A scientist in white lab coat examines cancer cell slides under a fluorescence microscope. Amber glass vials with pharmaceutical compounds line the stainless steel bench. Biosafety c
Merck US58933Y1055 Onkologie-Labor: Wissenschaftler am Mikroskop analysiert Krebszellen, mehrere Wirkstoff-Vials stehen auf der Werkbank, Illustration mit AI erstellt.

Merck stock closed at USD 151.81 on the NYSE on September 22, 2026, gaining 1.97 percent from the prior close. The shares outperformed the S&P 500, which rose 1.49 percent to 7,764.70 on the same session.

September 22, 2026 in numbers

Merck & Co., Inc. (ISIN US58933Y1055, NYSE: MRK) opened at USD 149.50 and reached USD 152.02 in New York trading. The stock finished USD 5.11 below its 52-week high of USD 156.92, based on market data reported on September 22.

The session followed Japan's approval of KEYTRUDA QLEX, a subcutaneous version of Merck's cancer treatment, according to Simply Wall St. Merck also received a U.S. label update for WINREVAIR after FDA approval based on the Phase 3 HYPERION trial, as reported by MarketBeat.

After the bell today

Merck's next quarterly reporting date was cited as October 29, 2026, when third-quarter figures are scheduled, according to AD HOC NEWS.

Disclaimer...

en | US58933Y1055 | MERCK & CO. | boerse | 70160159 | bgmi